# Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT

> **NCT03689894** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dartmouth-Hitchcock Medical Center** · enrollment: 2 (actual)

## Conditions studied

- Chronic Graft-versus-host-disease

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT03689894
- **Lead sponsor:** Dartmouth-Hitchcock Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-04-11
- **Primary completion:** 2021-09-20
- **Final completion:** 2021-09-20
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Insufficient accrual
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03689894

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03689894, "Ibrutinib Plus Rituximab for cGVHD Following Allo-SCT". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03689894. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*